FDA Import Refusal 1FX-2715618-2/10002/1 — Revance Therapeutics, Inc
The FDA refused shipment 1FX-2715618-2/10002/1 from Revance Therapeutics, Inc (United States) on Sep 8, 2026. The refused product falls under Drugs and Biologics — DAXIBOTULINUMTOXINA-LANM. Cited charges: 342,9999985 This firm has 3 other import refusals on record.
Refusal Details
- Date
- Sep 8, 2026
- Country
- United States
- Product Category
- Drugs and Biologics
- Product Code
- 58PDP04 DAXIBOTULINUMTOXINA-LANM
- Charges
- 342,9999985